FDA Approves TYLENOL with Naproxen OTC Combo

Key Takeaways

• FDA approved the first OTC fixed-dose acetaminophen + naproxen sodium combination (650 mg / 220 mg).
• Kenvue cited onset under 30 minutes and 12-hour duration from a single dose.
• Eight clinical studies reportedly showed superiority versus either ingredient alone.
• FDA granted three-year exclusivity for the new OTC formulation, per the company.

TYLENOL with Naproxen at a glance

Field	Detail
Product	TYLENOL with Naproxen (acetaminophen 650 mg + naproxen sodium 220 mg)
Company	Kenvue Inc. (TYLENOL brand)
FDA action	OTC approval announced July 24, 2026
Claimed onset / duration	Under 30 minutes; 12 hours
Evidence package	Eight clinical studies vs each monotherapy
Exclusivity	Three-year OTC formulation exclusivity (company)
Class	Non-opioid multimodal OTC analgesic

What did the FDA approve?

Kenvue said the FDA approved TYLENOL with Naproxen as the first and only OTC fixed-dose combination of acetaminophen and naproxen sodium. The product pairs a higher OTC acetaminophen dose with an NSAID dose matching common naproxen sodium strengths, intended to simplify multimodal pain relief without a prescription.

Company detail is in Kenvue's July 24 PR Newswire approval release. FDA also posted a related drug-news notice on FDA's nonprescription acetaminophen-naproxen combination page.

What problem is the combo meant to solve?

Kenvue cited a March 2026 Pain Consumer Survey (n=6,240) in which about 75% of persistent-pain sufferers reported dissatisfaction with current options. The company also referenced U.S. Department of Labor figures that up to 1 in 4 patients prescribed opioids are at risk of addiction, positioning the OTC combo as a non-opioid alternative to multi-product or prescription regimens.

Broader federal opioid-context materials sit on CDC overdose-prevention pages.

What efficacy claims did Kenvue make?

• Superior pain relief versus acetaminophen alone and naproxen sodium 220 mg alone across eight studies
• Onset of relief in under 30 minutes
• Duration of relief for 12 hours in a single dose

Congress presentations, including PAINWeek 2026, are expected to carry the detailed pain-model results. Labelled dosing, hepatic/NSAID warnings, and Drug Facts box language will govern real-world use.

What remains uncertain?

Company survey statistics and superiority claims should be read against the final OTC Drug Facts and clinical-study reports, not the launch wire alone. Liver-toxicity risk from acetaminophen and GI/CV risks from NSAIDs still apply. Launch timing, SKU mix, and retailer rollout were not detailed in the announcement.

Related NovaPharma coverage

• FDA approves OTC Rextovy, broadening naloxone access
• Lilly buys 4E in non-opioid pain push
• Compounded GLP-1s Why doctors worry and FDA acts

Frequently Asked Questions

Primary Sources

1. PR Newswire: Kenvue — TYLENOL with Naproxen FDA approval — July 24, 2026
2. FDA: First nonprescription acetaminophen-naproxen sodium combination
3. CDC: Overdose prevention